No. | Internal ID | Principal Investigator | Protocol ID | Phase | Sponsor |
---|---|---|---|---|---|
1. | GYFKK/157/2016 | Prof. Dr. Kovács Péter | 155b16 | I. | PRS Kft. |
2. | GYFKK/151/2016 | Prof. Dr. Altorjay István | LYC-30937-2002 | II. | ICON Klinikai Kutató Kft. |
3. | GYFKK/148/2016 | Dr. Kocsis Judit | CA209-649 | III. | Bristol-Myers Squibb Kft. |
4. | GYFKK/141/2016 | Prof. Dr. Altorjay István | GA29144 | III. | Quintiles Mo. Kft. |
5. | GYFKK/127/2016 | Prof. Dr. Zeher Margit | D3461C00008 | II. | AstraZeneca Kft. |
6. | GYFKK/100/2016 | Dr. Csépány Tünde | OBS13434 | BNJ. | Sanofi-Aventis Zrt. |
7. | GYFKK/149/2016 | Dr. Kocsis Judit | GS-US296-2013 | II. | Gilead Sciences Inc. |
8. | GYFKK/154/2016 | Prof. Dr. Szűcs Gabriella | SL0023 | II/B. | INC Research Kft. |
9. | GYFKK/140/2016 | Prof. Dr. Altorjay István | 64304500CRD2001 | II/B. | Janssen-Cilag Kft. |
10. | GYFKK/3/2017 | Prof. Dr. Altorjay István | GA29145 | III. | Quintiles Mo. Kft. |
11. | GYFKK/146/2016 | Prof. Dr. Kiss Csongor | DU176b-D-U312 | III. | Quintiles Mo. Kft. |
12. | GYFKK/131/2016 | Prof. Dr. Zeher Margit | SL0023 | II/B. | UCB Biopharma SPRL |
13. | GYFKK/33/2017 | Prof. Dr. Paragh György | K-877-303 | III. | Medpace Inc. |
14. | GYFKK/34/2017 | Prof. Dr. Paragh György | K-877-301 | III. | Medpace Inc. |
15. | GYFKK/4/2017 | Prof. Dr. Altorjay István | MLN000SC2-3027 | II. | Takeda Ltd. |
16. | GYFKK/147/2016 | Dr. Horváth Zsolt | NC-6004-008 | I/II. | NanoCarries Co., Ltd. |
17. | GYFKK/7/2017 | Dr. Horváth Zsolt | CLEE011A2404 | III. | Novartis Hungária Kft. |
18. | GYFKK/6/2017 | Dr. Habil. Tóth László | EFC14146/SINUS-24 | III. | Sanofi-Aventis Zrt. |
19. | GYFKK/135/2016 | Dr. Szántó Sándor | AS0008 | II/B. | PRA Mo. Kft. |
20. | GYFKK/123/2016 | Prof. Dr. Méhes Gábor | MK3475-091 PEARLS | III. | Covance Hungária Kft. |
21. | GYFKK/20/2017 | Prof. Dr. Illés Árpád | ARGX-113-1603 | II. | Quintiles Mo. Kft. |
22. | GYFKK/153/2016 | Prof. Dr. Illés Árpád | ACT14596 | II. | Sanofi-Aventis Zrt. |
23. | GYFKK/11/2017 | Prof. Dr. Altorjay István | PTG-100-02 | II/B. | Covance Inc. |
24. | GYFKK/18/2017 | Prof. Dr. Kovács Péter | 553B16 | I. | PRS Kft. |
25. | GYFKK/125/2016 | Prof. Dr. Póka Róbert | MR308-3502 | III. | Mundipharma GmbH |
26. | GYFKK/67/2016 | Prof. Dr. Csiba László | 20160125 | BNJ. | Amgen Europe GmbH |
27. | GYFKK/142/2016 | Prof. Dr. Illés Árpád | 2215-CL-0302 | III. | Astellas Pharma |
28. | GYFKK/144/2016 | Prof. Dr. Kovács Péter | PRS-2016-03-1 | I. | PRS Kft. |
29. | GYFKK/35/2017 | Prof. Dr. Kovács Péter | 679B15 | I. | PRS Kft. |
30. | GYFKK/124/2016 | Prof. Dr. Illés Árpád | ACE-CL-309 | III. | PRA Mo. Kft. |
31. | GYFKK/26/2017 | Dr. Kocsis Judit | D419NC00001 | I. | Covance Hungária Kft. |
32. | GYFKK/9/2017 | Prof. Dr. Édes István | ENTRUST-AF PCI (DSE-EDO-01-15-EU) | III/B. | Daiichi Sankyo GmbH |
33. | GYFKK/139/2016 | Prof. Dr. Remenyik Éva | CAIN457A3403 | BNJ. | Novartis Hungária Kft. |
34. | GYFKK/15/2017 | Prof. Dr. Illés Árpád | CINC424A2411 | II. | Novartis Hungária Kft. |
35. | GYFKK/16/2017 | Prof. Dr. Édes István | CLCZ696G2301, PARADISE | III. | Novartis Hungária Kft. |
36. | GYFKK/155/2016 | Prof. Dr. Póka Róbert | GEN702 | II. | Genmab A/S |
37. | GYFKK/158/2016 | Prof. Dr. Altorjay István | MLN0002SC-3030 | III/B. | Takeda Ltd. |
38. | GYFKK/28/2017 | Dr. Fülöp Tibor | D168C00016 MEASURE | IV. | AstraZeneca Kft. |
39. | GYFKK/19/2017 | Prof. Dr. Kiss Csongor | 1160.106 | IIB/III. | Boehringer Ingelheim |
40. | GYFKK/49/2017 | Prof. Dr. Csanádi Zoltán | DU176b-C-E314 | III. | Daiichi Sankyo GmbH |
41. | GYFKK/27/2017 | Prof. Dr. Kovács Péter | CL1-55746-001 | I. | Institut de Recherches IS |
42. | GYFKK/44/2016 | Dr. Horváth Zsolt | BO17920 (S-AVANT) | BNJ. | GERCOR |
43. | GYFKK/17/2017 | Prof. Dr. Kiss Csongor | 1160.108 | III. | Boehringer Ingelheim |
44. | GYFKK/13/2017 | Dr. Vajas Attila | VGFTe-OD-1411 | III. | Regeneron Pharmaceuticals |
45. | GYFKK/136/2016 | Prof. Dr. Zeher Margit | B7981006 | II. | Parexel Mo Kft. |
46. | GYFKK/40/2017 | Prof. Dr. Csanádi Zoltán | DSE-EDO-01-16 EU ELIMINATE - AF | III/B. | Daiichi Sankyo GmbH |
47. | GYFKK/21/2017 | Prof. Dr. Illés Árpád | OP-103 | III. | Oncopeptides AB |
48. | GYFKK/46/2017 | Prof. Dr. Kovács Péter | 767B15 | I. | PRS Kft. |
49. | GYFKK/55/2017 | Prof. Dr. Frecska Ede | 54135419TRD3008 | III. | Janssen-Cilag Kft. |
50. | GYFKK/22/2017 | Prof. Dr. Szilasi Mária | C38072-AS-30066 | III. | TEVA-PPD |
51. | GYFKK/1/2017 | Prof. Dr. Szilasi Mária | ML-3341-306 | III. | MELINTA-PSI |
52. | GYFKK/2/2017 | Prof. Dr. Szilasi Mária | MK3475-091 (PEARLS) | III. | Merck-Covance |
53. | GYFKK/70/2017 | Prof. Dr. Paragh György | GS-200-002 | III. | Medpace Inc. |
54. | GYFKK/59/2017 | Prof. Dr. Remenyik Éva | CNTO1959PSO3009 | III. | Janssen-Cilag Kft. |
55. | GYFKK/25/2017 | Prof. Dr. Édes István | COOL-AMI PIVOTAL, EDC-3135 | II. | ZOLL Circulation |
56. | GYFKK/61/2017 | Prof. Dr. Paragh György | 1245,11 | III. | Boechringer Ingelheim |
57. | GYFKK/29/2017 | Prof. Dr. Altorjay István | GS-US-419-3895 | III. | Gilead Sciences Inc. |
58. | GYFKK/30/2017 | Prof. Dr. Altorjay István | GS-US-419-3896 | III. | Gilead Sciences Inc. |
59. | GYFKK/31/2017 | Prof. Dr. Altorjay István | GS-US-418-3898 | IIB/III. | Gilead Sciences Inc. |
60. | GYFKK/32/2017 | Prof. Dr. Altorjay István | GS-US-418-3899 | III. | Gilead Sciences Inc. |
61. | GYFKK/45/2017 | Prof. Dr. Fülesdi Béla | ASN100-201 | II. | Arsanis Inc. |
62. | GYFKK/75/2017 | Prof. Dr. Kovács Péter | 187B16 | I. | PRS Kft. |
63. | GYFKK/48/2017 | Dr. Kocsis Judit | CO39385 | III. | F. Hoffmann-La Roche |
64. | GYFKK/45/2017 | Dr. Hidasi Eszter | KPASES 04/2016-Ralago/HU | IV. | KRKA Magyarország Kft. |
65. | GYFKK/24/2017 | Dr. Kocsis Judit | FLO-02 | I/II. | Menarini Ricerche S.P.A. |
66. | GYFKK/12/2017 | Dr. Horváth Zsolt | I3Y-MC-JPCJ | II. | Lilly Hungária Kft. |
67. | GYFKK/44/2017 | Dr. Szűcs Gabriella | CL010-168 | III. | Medpace Hungary Kft. |
68. | GYFKK/51/2017 | Dr. Szántó Sándor | CL04041023 (CREDO 2) | III. | Quintiles Mo. Kft. |
69. | GYFKK/58/2017 | Prof. Dr. Méhes Gábor | CPDR001X2101 | I/II. | Novartis Hungary Ltd. |
70. | GYFKK/8/2017 | Prof. Dr. Paragh György | NN1250-4252 | III/B | Novo-Nordisk |
71. | GYFKK/50/2017 | Prof. Dr. Dankó Katalin | GAM10-08 | III. | Octapharma GmbH |
72. | GYFKK/71/2017 | Prof. Dr. Balla György | CCD-01534CA1-01 | II. | Quintiles Mo. Kft. |
73. | GYFKK/60/2017 | Dr. Horváth Zsolt | SPI-GCF-302 | III. | Spectrum Pharmaceuticals |
74. | GYFKK/47/2017 | Dr. Horváth Zsolt | CTMX-M-072-001-7002 | I. | CytomX Therapeutics Inc. |
75. | GYFKK/73/2017 | Prof. Dr. Páll Dénes | ACHT 41 | BNJ. | George Clinical |
76. | GYFKK/68/2017 | Prof. Dr. Szilasi Mária | D5970C00002 | III/B. | AstraZeneca Kft. |
77. | GYFKK/24/2016 | Prof. Dr. Csiba László | ToL54304 | III. | Department of Neurology |
78. | GYFKK/42/2017 | Dr. Szántó Sándor | CAIN457F2366 | III/B. | Novartis Hungária Kft. |
79. | GYFKK/98/2017 | Prof. Dr. Paragh György | MT-8554-E06 | III. | ICON Klinikai Kutató Kft. |
80. | GYFKK/98/2016 | Prof. Dr. Szilasi Mária | M14-360 | II. | AbbVie Inc. |
81. | GYFKK/41/2017 | Dr. Bessenyei Mónika | UCB-EP0060 | II. | UCB Biosciences, Inc. |
82. | GYFKK/64/2017 | Prof. Dr. Póka Róbert | MVT-601-3002 | III. | Myovant Sciences GmbH |
83. | GYFKK/72/2017 | Prof. Dr. Póka Róbert | 16-OBE2109-009 | III. | OBSEVA |
Last update:
2023. 02. 16. 12:55